A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

Inclusion Criteria:

1. Adults ≥ 18 years of age.

2. Willing and able to provide signed and dated informed consent prior to anystudy-related procedures, and willing and able to comply with all study procedures

3. Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determinedby Investigator via medical records or in medical history obtained from the patient,is currently eligible for topical treatment and meets all the following criteria atscreening and baseline:

4. IGA ≥ 2 (5 score system)

5. Affected BSA 3%-15% (excluding head)

6. Agree not to have prolonged sun exposure (e.g., recreational) during the studyperiod. Tanning bed use or use of other light-emitting diodes (LEDs) is not allowed.

Exclusion Criteria:

1. Other types of psoriasis dominant other than plaque psoriasis (e.g., psoriaticarthritis, pustular, erythrodermic, guttate, palmar, plantar, scalp or nail disease)or the lesion is not eligible for topical treatment only.

2. Patients with any serious medical/psychiatric condition or clinically significantlaboratory abnormality that would prevent study participation or place the patientat significant risk, as determined by the Investigator.

3. Known or suspected:

4. Severe renal insufficiency or hepatic insufficiency.

5. History of severe depression or suicidal ideation or behavior within 2 yearsprior to screening.

6. Positive for any of the following tests at screening:

7. Human immunodeficiency virus (HIV): HIV antibody

8. Hepatitis B virus (HBV): hepatitis B surface antigen (HBsAg)/hepatitis B coreantibody (HBcAb)/HBV DNA

9. Hepatitis C virus (HCV): HCV RNA

10. Patients with active tuberculosis (TB) or untreated latent TB per local guidelines.

11. History of and/or concurrent condition of inflammatory bowel disease (IBD) (ulcerative colitis and Crohn's disease), or signs/symptoms of IBD at screeningthat, in the opinion of the Investigator, pose an unacceptable risk to the patientif participating in the study.

12. History of and/or concurrent condition of serious hypersensitivity (anaphylacticshock or anaphylactoid reaction) to IL-17 antibodies and any human or humanizedbiological agents.

13. Patients who have a history of malignancy unless deemed cured by adequate treatmentwith no evidence of recurrence for ≥ 3 years before the initiation of studytreatment.

14. Patients with a history of chronic alcohol or drug abuse within 6 months of theinitiation of study treatment, as determined by the Investigator.

15. Prior exposure to ZL-1102.

16. Patients who have received a live vaccine within 6 weeks prior to dosing on Day 1.

17. Females who are pregnant, wishing to become pregnant during the study, or arebreastfeeding